Evidence map›Paper›PMID 33101290›Full record

ArticleFrontiers in immunology2020

Inducible Bronchus-Associated Lymphoid Tissue (iBALT) Attenuates Pulmonary Pathology in a Mouse Model of Allergic Airway Disease.

Ji Young Hwang, Aaron Silva-Sanchez, Damian M Carragher, Maria de la Luz Garcia-Hernandez, Javier Rangel-Moreno, Troy D Randall

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Lung Lymphatics in Edema, Inflammation, and Thrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. CD4Frontiers in immunology · 2023
    Article
  16. DEPs Induce Local Ige Class Switching Independent of Their Ability to Stimulate iBALT de Novo Formation.International journal of environmental research and public health · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Short histological kaleidoscope - recent findings in histology. Part II.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ji Young HwangDivision of Clinical Immunology and Rheumatology, The Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Aaron Silva-SanchezDivision of Clinical Immunology and Rheumatology, The Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Damian M CarragherThe Trudeau Institute, Saranac Lake, NY, United States.
Maria de la Luz Garcia-HernandezDivision of Allergy Immunology and Rheumatology, The Department of Medicine, University of Rochester, Rochester, NY, United States.
Javier Rangel-MorenoDivision of Allergy Immunology and Rheumatology, The Department of Medicine, University of Rochester, Rochester, NY, United States.
Troy D RandallDivision of Clinical Immunology and Rheumatology, The Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
University of Rochester · USUniversity of Alabama at Birmingham · USTrudeau Institute · US

Funding

Unique Aspects of Respiratory ImmunityR01HL069409 · NHLBI · UNIVERSITY OF ROCHESTER · PI RANDALL, TROY D · 2001 to 2015
$5.3M
Central and Effector B cells in the LungR01AI097357 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI RANDALL, TROY D · 2012 to 2016
$1.8M
NHLBI NIH HHS R01 HL069409NIAID NIH HHS R01 AI097357
6 · The paper itself

Abstract

Inducible Bronchus Associated Lymphoid Tissue (iBALT) is an ectopic lymphoid tissue associated with severe forms of chronic lung diseases, including chronic obstructive pulmonary disease, rheumatoid lung disease, hypersensitivity pneumonitis and asthma, suggesting that iBALT may exacerbate these clinical conditions. However, despite the link between pulmonary pathology and iBALT formation, the role of iBALT in pathogenesis remains unknown. Here we tested whether the presence of iBALT in the lung prior to sensitization and challenge with a pulmonary allergen altered the biological outcome of disease. We found that the presence of iBALT did not exacerbate Th2 responses to pulmonary sensitization with ovalbumin. Instead, we found that mice with iBALT exhibited delayed Th2 accumulation in the lung, reduced eosinophil recruitment, reduced goblet cell hyperplasia and reduced mucus production. The presence of iBALT did not alter Th2 priming, but instead delayed the accumulation of Th2 cells in the lung following challenge and altered the spatial distribution of T cells in the lung. These results suggest that the formation of iBALT and sequestration of effector T cells in the context of chronic pulmonary inflammation may be a mechanism by which the immune system attenuates pulmonary inflammation and prevents excessive pathology.

Indexed as

AnimalsBronchiDisease Models, AnimalHumansHypersensitivityImmunity, MucosalInflammationLungLymphocyte ActivationLymphoid TissueMiceMice, Inbred C57BLMice, TransgenicRespiratory SystemTh2 Cellsasthmaectopic lymphoid tissueinducible bronchus associated lymphoid tissuepulmonary allergypulmonary inflammation

Identifiers

PMID33101290
PMCPMC7545112
OpenAlexW3088565814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.